Onconova Therapeutics, Inc.
http://www.onconova.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Onconova Therapeutics, Inc.
Onconova On The Edge After Phase III Rigosertib MDS Failure
Onconova’s lead product, rigosertib, has failed in a Phase III study in myelodysplastic syndromes, sending its share price tumbling by 66%.
Asia Deal Watch: China’s BravoVax, US-based GeoVax Team Up On Coronavirus Vaccine
Deal news from GeoVax/BravoVax, Onconova/HanX, Zydus Cadila/China Medical System Holdings, EyePoint/Ocumension, Ningbo NewBay Medical/Genentech, Otsuka/PhoreMost, Almirall/WuXi Biologics
Deal Watch: AstraZeneca Continues Divestments By Offloading US/Canada Seroquel Rights
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.
Deal Watch: Parvus Signs Second Big Pharma Alliance, With Genentech
Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with Genentech. Iconic licenses ADC tech from Zymeworks, then out-licenses lead candidate to Exelixis.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals